![Michael Cloonan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Cloonan
Vorstandsvorsitzender bei
SIONNA THERAPEUTICS, INC.
Vermögen: 24 Mio $ am 30.06.2026
Profil
Michael Cloonan ist Chief Operating Officer von SAGE Therapeutics, Inc. In der Vergangenheit hatte er die Position des Senior Vice President-US Commercial bei Biogen, Inc. inne. Herr Cloonan erhielt einen MBA von der University of Virginia Darden School of Business und einen Bachelor-Abschluss vom College of the Holy Cross (Massachusetts).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.04.2026 | 547.343 ( 1,21 % ) | 24 Mio $ | 30.06.2026 |
Aktive Positionen von Michael Cloonan
| Unternehmen | Position | Beginn |
|---|---|---|
| SIONNA THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.05.2021 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Berater | - |
Ehemalige bekannte Positionen von Michael Cloonan
| Unternehmen | Position | Ende |
|---|---|---|
| GENETIX BIOTHERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 02.06.2025 |
| SAGE THERAPEUTICS, INC. | Geschäftsführer | 03.05.2021 |
| BIOGEN INC. | Corporate Officer/Principal | 01.01.2017 |
Ausbildung von Michael Cloonan
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
83
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
College of the Holy Cross (Massachusetts)
 College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
SAGE Therapeutics, Inc.
 SAGE Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel medicines for central nervous system disorders | Health Technology |
University of Virginia Darden School of Business
 University of Virginia Darden School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
Wählen Sie MarketScreener 
